In a randomized trial of 60 community-dwelling adults aged 60-75, 12 weeks of supervised resistance training (three sessions weekly) increased maximal inspiratory and expiratory pressures, handgrip strength and 1-minute sit-to-stand performance versus controls. Trained participants also showed less exercise-induced oxygen desaturation, lower plasma IL-6, and markedly higher IL-10 and the anti-aging protein Klotho. Hematological markers and body measurements barely moved.
The functional results fit a large body of evidence that lifting counters sarcopenia, but the respiratory findings add something useful: breathing muscles respond to whole-body strength work even without dedicated inspiratory training, which matters because weak respiratory muscles predict falls, pneumonia risk and loss of independence. The Klotho result is the headline-grabber, and it deserves caution. Klotho is a plausible marker of biological aging, yet it is not a validated surrogate for lifespan or disease outcomes, circulating levels are assay-sensitive, and a rise over 12 weeks does not show that aging itself slowed. The same applies to the cytokine shifts, which are mechanistic signals rather than clinical endpoints. With only 60 participants, a short intervention, an apparently non-active control group, and no hard outcomes such as hospitalizations or mortality, this is a confirmatory trial with an exploratory biomarker layer. The practical message is conservative and sound: older adults gain measurable strength and respiratory benefit from thrice-weekly resistance training, and the biomarker story needs larger, longer replication.